[Expert consensus on the diagnosis and treatment of bone metastasis in lung cancer (2014 version)].
Yan Sun(Chinese Academy of Medical Sciences & Peking Union Medical College), Ying Cheng(Jilin Province Tumor Hospital), Lili Tang(Ministry of Education), Xiaohui Niu(Peking University), Jianchun Duan(Chinese Academy of Medical Sciences & Peking Union Medical College), Qisen Guo(Shandong Tumor Hospital), Jie Wang(Jishou University), Changli Wang(Second Military Medical University), Yuankai Shi(Chinese Academy of Medical Sciences & Peking Union Medical College), Qinghua Zhou(Sichuan University), Jun Liang(Army Medical University), Yiping Zhang(Zhejiang Cancer Hospital), Xiuyi Zhi(Roswell Park Comprehensive Cancer Center), Zhongzhen Guan(Dalian Jiaotong University), Jingnan Shen(Sun Yat-sen University), Yingjian Zhang(Henan University of Technology), Yunpeng Liu(Shenyang Institute of Automation), Meilin Liao(Shanghai Chest Hospital), Gongyan Chen(Harbin Medical University), Xin Yu(Peking University), Caicun Zhou(Tongji University), Yue Yang(Xijing Hospital), Mengzhong Liu(Sun Yat-sen University)
Cited by 21
Related Papers
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k